PURPOSE: The purpose of our study was to evaluate the degree of radiotoxicity to lymphocytes in thyroid cancer after iodine-131(I-131) therapy using γ-H2AX foci immunodetection. METHODS: This study focused on 15 patients who underwent I-131 therapy for differentiated thyroid cancer after surgery. All patients received 3.7 GBq of I-131. Venous blood samples were collected from each patient before therapy and 4 days thereafter. Lymphocytes were isolated from the blood samples and subjected to γ-H2AX immunofluorescence staining. RESULTS: The number (mean ± SD) of foci per lymphocyte nucleus was 0.41 ± 0.51 before and 6.19 ± 1.80 after radioiodine therapy, and this difference was statistically significant (P = 0.001 < 0.05). Absorbed doses estimated for the 15 patients were 0.77 ± 0.31 Gy applying standard line in vitro external radiation doses. CONCLUSION: γ-H2AX foci immunodetection in lymphocytes may detect radiation-induced DNA damage associated with I-131 therapy for thyroid cancer, and may facilitate estimation of the radiation doses absorbed with this therapy.
PURPOSE: The purpose of our study was to evaluate the degree of radiotoxicity to lymphocytes in thyroid cancer after iodine-131(I-131) therapy using γ-H2AX foci immunodetection. METHODS: This study focused on 15 patients who underwent I-131 therapy for differentiated thyroid cancer after surgery. All patients received 3.7 GBq of I-131. Venous blood samples were collected from each patient before therapy and 4 days thereafter. Lymphocytes were isolated from the blood samples and subjected to γ-H2AX immunofluorescence staining. RESULTS: The number (mean ± SD) of foci per lymphocyte nucleus was 0.41 ± 0.51 before and 6.19 ± 1.80 after radioiodine therapy, and this difference was statistically significant (P = 0.001 < 0.05). Absorbed doses estimated for the 15 patients were 0.77 ± 0.31 Gy applying standard line in vitro external radiation doses. CONCLUSION: γ-H2AX foci immunodetection in lymphocytes may detect radiation-induced DNA damage associated with I-131 therapy for thyroid cancer, and may facilitate estimation of the radiation doses absorbed with this therapy.
Authors: Uta Eberlein; Carina Nowak; Christina Bluemel; Andreas Konrad Buck; Rudolf Alexander Werner; Harry Scherthan; Michael Lassmann Journal: Eur J Nucl Med Mol Imaging Date: 2015-06-06 Impact factor: 9.236
Authors: Sarah Schumann; Harry Scherthan; Constantin Lapa; Sebastian Serfling; Razan Muhtadi; Michael Lassmann; Uta Eberlein Journal: Eur J Nucl Med Mol Imaging Date: 2019-04-27 Impact factor: 9.236
Authors: A Giussani; M A Lopez; H Romm; A Testa; E A Ainsbury; M Degteva; S Della Monaca; G Etherington; P Fattibene; I Güclu; A Jaworska; D C Lloyd; I Malátová; S McComish; D Melo; J Osko; A Rojo; S Roch-Lefevre; L Roy; E Shishkina; N Sotnik; S Y Tolmachev; A Wieser; C Woda; M Youngman Journal: Radiat Environ Biophys Date: 2020-05-05 Impact factor: 1.925
Authors: Luís S Santos; Octávia M Gil; Susana N Silva; Bruno C Gomes; Teresa C Ferreira; Edward Limbert; José Rueff Journal: Genes (Basel) Date: 2020-09-17 Impact factor: 4.096